PBI20 SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE...

Value in Health 2019 / 11 Vol. 22

PBI20 SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A GREEK PERSPECTIVE

Daoussis, D., Theofanidis, N., Kalogeropoulou, M.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.124
Date:
November, 2019
File:
PDF, 712 KB
2019
Conversion to is in progress
Conversion to is failed